Delivery of therapeutic peptides or proteins into tissues is severely limited by the size and biochemical properties of the molecules. Protein transduction domain (PTD)-mediated cargo transduction represents a novel a...Delivery of therapeutic peptides or proteins into tissues is severely limited by the size and biochemical properties of the molecules. Protein transduction domain (PTD)-mediated cargo transduction represents a novel and promising strategy to deliver biologically active peptides in vivo. The first PTD was identified from the HIV-1 transactivating transcriptional activator protein Tat in 1988. Since then, other PTDs have also been identified, including the third α-helix of the antennapedia homeotic transcription factor and synthetic peptide carriers. However, Tat PTD (amino acids 47 - 57) has shown markedly better ability for intracellular delivery than other PTDs. It has been demonstrated that fusion peptides containing the Tat PTD enter the central nervous system after systemic administration. Our previous study has shown that i.p. injected Tat-PSD-95 PDZ2 expresses in the central nervous system and significantly disrupts PDZ domain-mediated protein interactions between PSD-95 and N-methyl-D-aspartate receptor subunit NR2A/2B, thereby alleviating chronic pain. Therefore, Tat-mediated intracellular delivery can be used for systemic administration of analgesics in pain management.展开更多
PICK1蛋白(protein interacting with C alpha kinase 1)是一种同时具有PDZ和BAR区域的支架蛋白,在哺乳动物体内与多种蛋白质相互作用,并被证明在多种生理过程中发挥重要的调节作用,同时参与了多种疾病病理过程。因此,PICK1蛋白可能成...PICK1蛋白(protein interacting with C alpha kinase 1)是一种同时具有PDZ和BAR区域的支架蛋白,在哺乳动物体内与多种蛋白质相互作用,并被证明在多种生理过程中发挥重要的调节作用,同时参与了多种疾病病理过程。因此,PICK1蛋白可能成为极具前景的疾病治疗靶点。该文通过对近年来国内外发表的相关文献进行整理与分析,综述了PICK1蛋白的生理功能与其作为药物靶点的研究新进展,旨在为PICK1蛋白的深入研究提供理论支持。展开更多
蛋白质是生命功能的执行者.生命体中某些关键蛋白的功能异常往往是导致疾病发生的根本原因.这些疾病相关蛋白极有可能成为药物靶点,为新药研发和疾病治疗提供重要线索.PICK1蛋白(protein interacting with Cαkinase1)结合能力广泛、功...蛋白质是生命功能的执行者.生命体中某些关键蛋白的功能异常往往是导致疾病发生的根本原因.这些疾病相关蛋白极有可能成为药物靶点,为新药研发和疾病治疗提供重要线索.PICK1蛋白(protein interacting with Cαkinase1)结合能力广泛、功能多样以及在多种重要疾病(如:癌症、精神分裂症、疼痛、帕金森综合症等)的发生发展过程中发挥潜在的作用,使其成为一个可能的药靶蛋白.PICK1与绝大多数配体蛋白的相互作用是通过其PDZ结构域与配体C末端区域的结合介导的,使PICK1的PDZ结构域成为一个潜在的药物靶点.因此,可以利用生物小分子物质特异性地结合PICK1的PDZ结构域,干扰或阻断PICK1与配体蛋白的天然相互作用,最终达到治疗相关疾病的目的.展开更多
蛋白激酶Cα相互作用蛋白1(protein interacting with Cαkinase 1,PICK1)是衔接膜上受体和蛋白激酶Cα的重要蛋白.利用荧光光谱结合定点突变技术、蛋白与脂质覆盖法等方法,分析了PICK1蛋白N末端区域几个酸性氨基酸残基对PDZ结构域与膜...蛋白激酶Cα相互作用蛋白1(protein interacting with Cαkinase 1,PICK1)是衔接膜上受体和蛋白激酶Cα的重要蛋白.利用荧光光谱结合定点突变技术、蛋白与脂质覆盖法等方法,分析了PICK1蛋白N末端区域几个酸性氨基酸残基对PDZ结构域与膜脂结合的影响,以及钙离子结合N末端酸性区域对PDZ脂结合能力的调节.结果显示,带有上游酸性区域的PDZ结构域(NPDZ)的脂质结合能力仅相当PDZ结构域的15%,相比单独的PDZ结构域与脂质的解离常数Kd(PDZ)为1.58×103μg.L-1,NPDZ与脂质解离常数Kd(NPDZ)为3.3×104μg.L-1,其中在N末端酸性残基中D8与D12两个天冬氨酸是影响脂质结合能力减弱的关键残基,若将二者分别突变为丙氨酸后,NPDZ与脂质的解离常数分别为:Kd(D8/A)=4.42×103μg.L-1;Kd(D12/A)=1.73×103μg.L-1接近于PDZ结构域与脂质结合能力;钙离子会增强NPDZ脂结合能力,当钙离子浓度达到30μmol/L时,NPDZ的脂结合能力提高2.3倍,但只相当于PDZ的50%的结合能力.展开更多
Platelets have essential roles in both health and disease. Normal platelet function is required for hemostasis.Inhibition of platelet function in disease or by pharmacological treatment results in bleeding disorders.O...Platelets have essential roles in both health and disease. Normal platelet function is required for hemostasis.Inhibition of platelet function in disease or by pharmacological treatment results in bleeding disorders.On the other hand,hyperactive platelets lead to heart attack and stroke.Calcium is a major second messenger in platelet activation,and elevated intracellular calcium leads to hyperactive platelets.Elevated platelet calcium has been documented in hypertension and diabetes;both conditions increase the likelihood of heart attack and stroke. Thus,proper regulation of calcium metabolism in the platelet is extremely important.Plasma membrane Ca2+-ATPase(PMCA)is a major player in platelet calcium metabolism since it provides the only significant route for calcium efflux.In keeping with the important role of calcium in platelet function,PMCA is a highly regulated transporter.In human platelets,PMCA is activated by Ca2+/calmodulin,by cAMP-dependent phosphorylation and by calpain-dependent removal of the inhibitory peptide.It is inhibited by tyrosine phosphorylation and calpain-dependent proteolysis.In addition,the cellular location of PMCA is regulated by a PDZ-domain-dependent interaction with the cytoskeleton during platelet activation.Rapid regulation by phosphorylation results in changes in the rate of platelet activation,whereas calpain-dependent proteolysis and interaction with the cytoskeleton appears to regulate later events such as clot retraction.In hypertension and diabetes,PMCA expression is upregulated while activity is decreased, presumably due to tyrosine phosphorylation.Clearly,a more complete understanding of PMCA function in human platelets could result in the identification of new ways to control platelet function in disease states.展开更多
PICK1(protein interacting with C kinase 1)是一种含PDZ(PSD-95/Dlg/ZO1)结构域和BAR(Bin/amphiphysin/Rvs)结构域的蛋白,它可通过PDZ结构域与多种蛋白发生相互作用,其中一些蛋白与中枢神经系统(CNS)疾病密切相关。文中综述了近年来关...PICK1(protein interacting with C kinase 1)是一种含PDZ(PSD-95/Dlg/ZO1)结构域和BAR(Bin/amphiphysin/Rvs)结构域的蛋白,它可通过PDZ结构域与多种蛋白发生相互作用,其中一些蛋白与中枢神经系统(CNS)疾病密切相关。文中综述了近年来关于PICK1在几种中枢神经系统疾病中的作用研究,以期对疾病研究和临床治疗提供参考。展开更多
目的:研究PICK1(protein interacting with C kinase 1)蛋白PDZ结构域内83位点赖氨酸(K83)对PICK1和AMPA受体GluR2亚单位相互作用的影响。方法:利用计算机对PICK1 PDZ结构域和GluR2 C末端4个氨基酸残基进行对接模拟,然后将K83进行虚拟...目的:研究PICK1(protein interacting with C kinase 1)蛋白PDZ结构域内83位点赖氨酸(K83)对PICK1和AMPA受体GluR2亚单位相互作用的影响。方法:利用计算机对PICK1 PDZ结构域和GluR2 C末端4个氨基酸残基进行对接模拟,然后将K83进行虚拟点突变,计算并观察突变后结构和键能的改变。利用实验室已有的野生型全长PICK1 cDNA质粒为模板,构建点突变质粒,与野生型GluR2共转到HEK293T细胞,观察两者在细胞内定位和分布的改变。结果:当野生型PICK1与GluR2共转染时,HEK293T细胞有大量PICK1和GluR2共定位的集簇(cluster)。当我们把构建的PICK1突变体与GluR2共转染时,不同的突变体表现出不一样的改变。结论:改变K83位点的氨基酸结构,很可能会改变PICK1 PDZ结构域与GluR2 C末端结合所形成的疏水、氢键、静电相互作用,使得PDZ结构域与GluR2 C末端的结合能力发生不同程度的改变。展开更多
文摘Delivery of therapeutic peptides or proteins into tissues is severely limited by the size and biochemical properties of the molecules. Protein transduction domain (PTD)-mediated cargo transduction represents a novel and promising strategy to deliver biologically active peptides in vivo. The first PTD was identified from the HIV-1 transactivating transcriptional activator protein Tat in 1988. Since then, other PTDs have also been identified, including the third α-helix of the antennapedia homeotic transcription factor and synthetic peptide carriers. However, Tat PTD (amino acids 47 - 57) has shown markedly better ability for intracellular delivery than other PTDs. It has been demonstrated that fusion peptides containing the Tat PTD enter the central nervous system after systemic administration. Our previous study has shown that i.p. injected Tat-PSD-95 PDZ2 expresses in the central nervous system and significantly disrupts PDZ domain-mediated protein interactions between PSD-95 and N-methyl-D-aspartate receptor subunit NR2A/2B, thereby alleviating chronic pain. Therefore, Tat-mediated intracellular delivery can be used for systemic administration of analgesics in pain management.
文摘PICK1蛋白(protein interacting with C alpha kinase 1)是一种同时具有PDZ和BAR区域的支架蛋白,在哺乳动物体内与多种蛋白质相互作用,并被证明在多种生理过程中发挥重要的调节作用,同时参与了多种疾病病理过程。因此,PICK1蛋白可能成为极具前景的疾病治疗靶点。该文通过对近年来国内外发表的相关文献进行整理与分析,综述了PICK1蛋白的生理功能与其作为药物靶点的研究新进展,旨在为PICK1蛋白的深入研究提供理论支持。
文摘蛋白质是生命功能的执行者.生命体中某些关键蛋白的功能异常往往是导致疾病发生的根本原因.这些疾病相关蛋白极有可能成为药物靶点,为新药研发和疾病治疗提供重要线索.PICK1蛋白(protein interacting with Cαkinase1)结合能力广泛、功能多样以及在多种重要疾病(如:癌症、精神分裂症、疼痛、帕金森综合症等)的发生发展过程中发挥潜在的作用,使其成为一个可能的药靶蛋白.PICK1与绝大多数配体蛋白的相互作用是通过其PDZ结构域与配体C末端区域的结合介导的,使PICK1的PDZ结构域成为一个潜在的药物靶点.因此,可以利用生物小分子物质特异性地结合PICK1的PDZ结构域,干扰或阻断PICK1与配体蛋白的天然相互作用,最终达到治疗相关疾病的目的.
基金Suported by Ministry of Science and Technology Student of China Project 973(2007CB914301)National Natural Science Foundation of China(3100345)The 111Project(B08011)
文摘蛋白激酶Cα相互作用蛋白1(protein interacting with Cαkinase 1,PICK1)是衔接膜上受体和蛋白激酶Cα的重要蛋白.利用荧光光谱结合定点突变技术、蛋白与脂质覆盖法等方法,分析了PICK1蛋白N末端区域几个酸性氨基酸残基对PDZ结构域与膜脂结合的影响,以及钙离子结合N末端酸性区域对PDZ脂结合能力的调节.结果显示,带有上游酸性区域的PDZ结构域(NPDZ)的脂质结合能力仅相当PDZ结构域的15%,相比单独的PDZ结构域与脂质的解离常数Kd(PDZ)为1.58×103μg.L-1,NPDZ与脂质解离常数Kd(NPDZ)为3.3×104μg.L-1,其中在N末端酸性残基中D8与D12两个天冬氨酸是影响脂质结合能力减弱的关键残基,若将二者分别突变为丙氨酸后,NPDZ与脂质的解离常数分别为:Kd(D8/A)=4.42×103μg.L-1;Kd(D12/A)=1.73×103μg.L-1接近于PDZ结构域与脂质结合能力;钙离子会增强NPDZ脂结合能力,当钙离子浓度达到30μmol/L时,NPDZ的脂结合能力提高2.3倍,但只相当于PDZ的50%的结合能力.
文摘Platelets have essential roles in both health and disease. Normal platelet function is required for hemostasis.Inhibition of platelet function in disease or by pharmacological treatment results in bleeding disorders.On the other hand,hyperactive platelets lead to heart attack and stroke.Calcium is a major second messenger in platelet activation,and elevated intracellular calcium leads to hyperactive platelets.Elevated platelet calcium has been documented in hypertension and diabetes;both conditions increase the likelihood of heart attack and stroke. Thus,proper regulation of calcium metabolism in the platelet is extremely important.Plasma membrane Ca2+-ATPase(PMCA)is a major player in platelet calcium metabolism since it provides the only significant route for calcium efflux.In keeping with the important role of calcium in platelet function,PMCA is a highly regulated transporter.In human platelets,PMCA is activated by Ca2+/calmodulin,by cAMP-dependent phosphorylation and by calpain-dependent removal of the inhibitory peptide.It is inhibited by tyrosine phosphorylation and calpain-dependent proteolysis.In addition,the cellular location of PMCA is regulated by a PDZ-domain-dependent interaction with the cytoskeleton during platelet activation.Rapid regulation by phosphorylation results in changes in the rate of platelet activation,whereas calpain-dependent proteolysis and interaction with the cytoskeleton appears to regulate later events such as clot retraction.In hypertension and diabetes,PMCA expression is upregulated while activity is decreased, presumably due to tyrosine phosphorylation.Clearly,a more complete understanding of PMCA function in human platelets could result in the identification of new ways to control platelet function in disease states.
文摘PICK1(protein interacting with C kinase 1)是一种含PDZ(PSD-95/Dlg/ZO1)结构域和BAR(Bin/amphiphysin/Rvs)结构域的蛋白,它可通过PDZ结构域与多种蛋白发生相互作用,其中一些蛋白与中枢神经系统(CNS)疾病密切相关。文中综述了近年来关于PICK1在几种中枢神经系统疾病中的作用研究,以期对疾病研究和临床治疗提供参考。
